Evaluation Of Dengue Fever Knowledge Among The General Population And Its Prevalence, Clinical Features In Penang General Hospital by Wazir, Khurshid Alam
  
  EVALUATION OF DENGUE FEVER KNOWLEDGE AMONG THE 
GENERAL POPULATION AND ITS PREVALENCE, CLINICAL 
FEATURES IN PENANG GENERAL HOSPITAL 
 
 
 
 
By 
 
 
KHURSHID ALAM WAZIR 
 
 
 
Thesis submitted in fulfillment of the 
Requirements for the degree of 
Master of Science 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
December 2009 
 
 
 
 
                                                          
 
  
 
 
 
 
 
 
 
 
Dedication 
My research is dedicated to my parents and my uncle Dr B.J. Wazir and 
Auntie Aishah Wazir 
 
 
 
 
 
 
 
 
iii  
ACKNOWLEDGEMENT 
 
I am very grateful to almighty ALLAH who gave me the capability to conduct such a 
research and completion of my thesis. I am thankful to those who helped me in 
compiling of my thesis. I deeply express my gratitude and appreciation to my supervisor 
Dr. Syed Azhar Syed Sulaiman and my co-supervisor Dr. Asrul Akmal Shafie for their 
supervision. 
 
I would like to thank to my field supervisor  Dato Dr.Rozina Ghazalli Head of 
Nephrology and staff at medical ward Penang GH for their guidance and help in 
conducting my study. 
 
I am especially obliged to Abdul Hadi who assisted me in my data collection. Special 
thanks to Hadeer Abdul Razak Akram, Muhammad Abdullah, Amer Hayat and 
Khurram Ghani who helped me in various matters of my study. 
 
May almighty ALLAH bless upon those who assisted me in any aspect 
                                                                                    Khurshid Aalm 
  
 
 
 
 
 
 
iv  
TABLE OF CONTENTS 
                                                                                                                                 Page 
ACKNOWLEDGEMENT..……………………….................................................. iii 
TABLE OF CONTENTS………………………………………………………….. iv 
LIST OF TABLES……………….………………………………………………… ix 
LIST OF FIGURES …………………………………………………………..…… x 
LIST OF ACRONYMS…………………………………………………….……… xi 
LIST OF APPENDIX…………………………………………...………………..... xiii 
 
ABSTRAK……………………………..……………………………………......….. xiv 
 
ABSTRACT………………………….………………………………………...…… xv 
 
 
     CHAPTER ONE – INTRODUCTION  
 
1.0     Introduction and literature review………………...……………………........... 1 
1.1    Background…………………………………...……………………………….. 1 
1.2    Epidemiology and prevalence of dengue fever……...…………………............ 2 
1.3    Prevalence in Malaysia……….……………………………………………….. 9                      
1.4    Disease Transmission………………………….………………………………. 13                  
1.5    Virology…………………………………………………….…………….…… 14 
1.6    Clinical features (manifestations) and pathophysiology…….………………… 15 
         1.6.1   Spectrum of dengue infection………………………………………….. 15 
         1.6.2   Clinical course of dengue infection…………….…………………….... 15 
              1.6.2.1   Febrile phase…………………….…………………………........... 15 
              1.6.2.2   Critical Phase…………………….…………………………..…… 16 
              1.6.2.3   Recovery phase…………..….………….………………………… 17                 
1.7    Pathophysiology of plasma leakage in (DHF) and   (DSS)..…….…………..... 19 
1.8    Assessment of the WHO classification and case definitions……...……...…… 22 
1.9    Tourniquet test (TT)………………………….……………………..…............. 24 
1.10  Other important manifestations……………..…………………………………. 25 
          1.10.1   Acute abdomen…………………….……………………..………….. 25  
          1.10.2.   Hepatitis and liver failure……….……………...……………………. 25 
v  
          1.10.3.   Neurological manifestation……….……………...………………….. 25               
1.11    Diagnostic challenges…………………………….…..………………............ 26 
           1.11.1   Febrile phase…………………….………………..…………............. 26  
           1.11.2   Critical phase……………………………………..…………………. 26             
1.12    Laboratory investigation………………….……………..………………….... 27 
           1.12.1   Full blood count…………………………….……………………….. 27 
                   1.12.1.1   White blood cells……………..…………………………….... 27 
                   1.12.1.2   Hematocrit (HCT)………………….…………………............ 27 
                   1.12.1.3   Thrombocytopenia…………………….……………............... 28  
           1.12.2   Liver Function Test…………………….……………………………. 28 
1.13     Diagnostic tests………………………………………………………............ 28 
1.14     Dengue serology tests………………………...……………………………... 29 
             1.14.1   Haemagglutination Inhibition Test………….………………........... 29 
             1.14.2   Dengue IgM test………………………….………………………… 29  
             1.14.3   Indirect IgG ELISA test………………….………………………… 30 
             1.14.4   Dengue Rapid tests…………………………….……………........... 30 
             1.14.5   False positive dengue serology………………..……………............ 30  
1.15     Virus isolation…………………………………….…………………............. 31 
1.16     Dengue Molecular methods………………………….………………............ 31 
             1.16.1   Polymerase chain reaction (PCR)………….………………….…… 31 
             1.16.2   Non structural protein -1 (NS1 Antigen)………….……………….. 32 
1.17     Treatment of dengue (Fluid management in children).……………………... 32 
1.18     Non shock patients (Fluid management in adult)…………….……............... 34 
1.19     Dengue Shock Syndrome (DSS) (DHF Grade III &IV)……..………........... 35 
1.20     Principles for fluid resuscitation……………………...………………..……. 36  
           1.20.1 Clinical parameters……………………………..…………………...... 36 
           1.20.2 Laboratory parameters…………………………..……………............. 36 
1.21     Management of bleeding and haemostasis…………..……………………… 37 
            1.21.1    Haemostatic Abnormalities in dengue Infection………...………… 37 
            1.21.2    Significant occult bleeding …………………..……………………. 37 
            1.21.3    Management of Bleeding in dengue……………..………………... 38 
            1.21.4    Management of upper gastrointestinal bleeding (UGIT)…………... 38                     
            1.21.5    The role of prophylactic transfusions in dengue………..…………. 39 
            1.21.6    The role of adjunctive therapy in dengue………….…………........ 39 
vi  
            1.21.7    Intensive care management…………………….…………………... 39 
1.22     Prevalence of Dengue fever…………………….…………………………....40 
1.23     Literature on dengue’s knowledge………………….…………………..….... 45 
1.24     Literature on clinical features and complications of dengue…….……..….... 51 
1.25     Literature of fluids management on dengue fever………...…………....….... 63 
1.26     Problem statement…………………………...…………………..……...….... 67 
1.27     Significance of the study……………………...…………………….......…....68 
1.28     Objectives ……………………………………..…………………….…........ 68 
 
      CHAPTER TWO –METHODOLOGY 
2.0     Study design A……………………………..…………………………………. 69 
2.1     Duration of the study…………………………...……………………….......... 69 
2.2     Ethical consideration……………………………...…………………………... 69 
2.3     Selection criteria of the study population ……...…………………….............. 69 
          2.3.1   Inclusion Criteria………………….………..…………….………….... 69 
          2.3.2   Exclusion Criteria ……………….……………….………………….... 70 
2.4     Sampling technique…………………………...…………………………......... 70 
2.5     Sample size calculation……………………………………...…………........... 70 
2.6     Instruments…………………………………………………………..…........... 71 
2.7     Validation of the questionnaire……………………….……………………..... 72 
2.8     Contents of the questionnaire…………………...…………………….....…..... 74 
2.9     Study population and administration of the questionnaire……..…………...... 74 
2.0     Study design B……………………………...…………………………............ 75 
2.1     Phase one………..………………………………………………………......... 75 
2.2     Phase two……………………………………………………………………... 75 
2.3     Study location…………………………………………………………............ 75  
2.4     Duration of the study…………………………………………………………. 76 
2.5     Ethical consideration…………………………………………………………..76 
2.6     Selection criteria of the study population ......................................................... 76 
      2.6.1   Inclusion Criteria……………………………………………………........ 76 
      2.6.2   Exclusion Criteria………………………………………………………... 76 
2.7    Sample size……………………………………………………………………. 76 
2.8    Instruments…………………………………………………………………….. 77 
2.9    Patients’ selection and duration of the study………………………………….. 77 
vii 
2.10   Data collection ……………………………………………………………….. 77 
2.11   Data analysis………………………………………………………………….. 78 
  
     CHAPTER THREE – RESULTS  
 
3.0      Description of the results…………………………...…………………....…... 79 
3.1      The respondents………………………...…………………………………..... 80 
           3.1.1   Socio demographic data ………………………………….................... 80                       
           3.1.2   Respondents who were ever heard about dengue fever………............. 82 
3.2      Source of information about dengue………………...……….......................... 83 
3.3      Basic knowledge about dengue fever of the respondents ……………............ 83 
3.4      Relationship between knowledge levels and races........................................... 84 
3.5      Relationship between knowledge levels and age groups.................................. 86 
3.6      Relationship between knowledge and employment …..................................... 88 
3.7      Relationship between knowledge and educational…………………………... 90 
3.8      Relationship between knowledge and gender...……………………………… 92 
3.9      Prevalence of the dengue disease based on gender……..………...…….……. 94 
3.10    Prevalence of the dengue disease according to age ………………………… 94 
3.11    Prevalence of the dengue disease according to races………………………. ..95 
3.12    Mean of the days during hospitalization ……………………………………. 95 
3.13    Clinical features of dengue fever on disease severity …………...…....…….. 96 
3.14    Clinical manifestations of dengue fever by age groups…………………...... ..97 
3.15    Laboratory findings in dengue patients .…………………...……………........ 99 
3.16    Laboratory findings on gender base……………………………………….... ..100 
3.17    Laboratory findings on the basis of age groups.………...………….................103 
3.18    Fluids management of dengue fever ………………………............................ 108 
3.19    Fluids distribution on the basis of age groups .……………...……….…….... 108 
3.20    Fluids distribution according to disease severity …………............................. 109 
3.20   Complication of dengue fever found in hospitalized patients………………....111 
 
 
 
 
 
viii  
      CHAPTER FOUR-DISCUSSION 
4.0     Study summary……………………………………………...………......……. 112 
4.1     Methodologically issues ..……………………………….……………............. 113 
4.2     Public knowledge on dengue…………………………...……………….……. 114 
4.3     Prevalence of dengue ………………………………………………...………. 126 
4.4     Duration of hospitalization of the patients based on disease…………......…... 129 
4.5     Dengue characteristics according to disease severity ………………………... 129 
4.6     Clinical manifestations of dengue fever in terms of age groups.………...….... 137 
4.7     Laboratory parameters at the time of admission and discharge…..…......……. 144 
4.8     Laboratory findings on the basis of gender and age groups……...…………... 146 
4.9     Fluids management of dengue fever……………………………….................. 151 
4.10   Complications and clinical outcome……………………...…………......……. 155 
 CHAPTER FIVE-CONCLUSION AND RECOMMENDATIONS 
5.0    Conclusion ……………………………………………………........…………. 157               
5.1    Limitations of the study………………………………………………..…..….. 158              
5.3    Future studies and recommendations…………………………...………..……. 159 
Bibliography………………………………………………...………..……….......... 161 
 
 
                                                   LIST OF TABLES  
 
 Table                                                 Title  
 
1.1    Age distribution of children in endemic Asian countries………..…….……......7 
1.2    Laboratory confirmed dengue cases in endemic Asian countries..……..............8 
1.3    Dengue fever in Malaysia 1999-2003……………………………..….…...........9 
1.4    Dengue deaths and case fatality rates by age in Malaysia (1999-2003)..............10 
1.5    A range of pathophysiological changes in dengue patients………….........…... 20 
1.6    Differential diagnoses for dengue illness during febrile phase.......................... 26 
1.7    Differential diagnoses for dengue illness during critical phase……….…..….. 27       
2.1    Knowledge level according to score…………...………………………............ 73 
3.1    Gender based participation………………………………..…........................... 81 
3.2    Age wise participation………..……...…………............................................... 81 
ix  
3.3    Races participation in the study………………………………………………...81 
3.4    Employment base participation in the study.…………………………………...81 
3.5    Respondents participation on educational level…………………………..........82 
3.6    Source of information..........................................................................................83 
3.7    Relationship between knowledge and races ……..………...…………………..85 
3.8    Relationship between knowledge and age groups …………….……………….87 
3.9   Relationship between knowledge and employment………..…………...............89 
3.10    Relationship between knowledge and educational ……………..………...…..91 
3.11    Relationship between knowledge and gender ……….....…..............................93 
3.12    Number of DF, DHF, DSS according to gender……………………………. ..94 
3.13    Frequency of DF, DHF and DSS according to age............................................94 
3.14    Number of DF, DHF and DSS according to the race………………………. ..95 
3.15    Mean of hospitalization for DF, DHF and DSS……...………...……………..95 
3.16    Clinical features according to disease severity …………..………......….........96       
3.17    Clinical manifestations of dengue fever in the age groups ………………...... 98 
3.18    Laboratory measures at the time of admission and discharge.......................... 99 
3.19   WBC on admission and discharge in gender.….....……...……………………100 
3.20    Haemotocrit concentration in gender……………………………………….. .100 
3.21    Hemoglobin level upon admission and discharge in gender …………….......101 
3.22    Platelets count on gender base upon admission and discharg………………..101 
3.23     Alanine transaminase on gender base upon ……………………………….............102 
3.24     Urea level upon admission and discharge on gender……. ………………….102 
3.25   White Blood Cells upon admission by age groups…. …….……….…………103    
3.26    White Blood Cells upon discharge by age groups…………………………....103 
3.27    Haematocrit concentrations upon admission …... …………….……………..104 
3.28    Haematocrit concentrations upon discharge………………………………….104 
3.29    Hemoglobin level at the time of admission……………... …………………..105 
3.30    Hemoglobin level at the time of discharge……………….…………………..105 
3.31    Platelet count at the time of admission ……………..………………………..106 
3.32    Platelet count at the time of discharge………………………………………..106 
3.33    Alanine transaminase level at the time of admission …………….…………..106 
3.34    Alanine transaminase level at the time of discharge………………………….107 
3.35    Urea at the time of admission and discharge…………………………………107 
3.36    Urea at the time of discharge…………………………………………………107 
x  
3.37    The frequencies of infusions in DF, DHF and DSS.……….………………...108 
3.38    Institution of normal saline solution in terms of age…………………………108 
3.39    Dextrose solution administration on age basis……………………….………109 
3.40    Distribution of normal saline solution on disease bases ……………………..109 
3.41    Distribution of 5% dextrose solutions on disease basis………………………110 
3.42    Potassium chloride (KCl) administration according to disease………………110 
3.43    Complication of dengue in patients…………………………………………..111 
 
 
LIST OF FIGURES 
 
Figure                                                   Title  
 
1.1     Number of dengue cases, Malaysia 1995-2007…………………………….... 11 
1.2     Dengue incidence rate by age group in Malaysia, 2003, 2007……..……….... 11 
1.3     Dengue deaths by age group, Malaysia……………………………………..... 12 
1.4     Dengue case fatality rate (CFR) by age group, Malaysia…………….. .……. 12 
1.5    Clinical course of dengue of DHF (Nimmannitya, 1987)…………….............. 18 
1.6    Dengue classification (WHO)………………………………………….. ….…. 22 
3.1    Response rate of the survey …………………………………………............... 80 
3.2    Respondents who were ever heard about dengue fever………………..…….... 82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi  
                                            LIST OF ABBREVIATIONS  
 
APTT Activated partial thromboplastin time 
ADEM acute disseminated encephalomyelitis 
ALT Alanine aminotransaminase 
AAT Alanine aminotransferase 
ALP alkaline phosphatase 
AMR Americas Region 
NS1 Antigen Non structural protein -1 
AST Aspartate aminotransaminase 
BP Blood pressure   
CFR Case fatality rate 
CNS Central nervous system 
CSF Cerebro spinal fluid 
CRC Clinical Research Committee 
CDC Communicable Diseases Centre                            
DEN Dengue 
DF Dengue Fever 
DHF Dengue hemorrhagic fever 
DSS Dengue shock syndrome 
DBP diastolic blood pressure 
DIC Disseminated Intravascular coagulopathy 
EMR Eastern Mediterranean Region 
ELISA enzyme-linked immunosorbent assay 
GGT Gamma glutamyltransferase 
GIT gastrointestinal tract 
HI Haemagglutination Inhibition 
HCT Haemotocrit 
IV intravenous 
KAP Knowledge practice attitude 
MOH Ministry of health 
NR Normal range 
NS normal saline solution 
PAHO Pan American health organization) 
PT Platelets 
PCR Polymerase chain reaction 
TDR Research and training in tropical diseases 
RT- PCR Reverse transcriptase polymerase chain reaction 
SWG Scientific Working Group 
SERI 
socio-economic and environmental research 
institute 
SEA South- East Asian countries 
SEAR South East Asian Region 
SEAR South-East Asia Region 
xii 
SPSS statistical package for social science 
SBP systolic blood pressure 
AFR The African region 
TT Tourniquet test 
UN United Nations 
WPR Western Pacific Region 
WPR Western Pacific Region 
WBCs White blood cells 
WP working paper 
WHO World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii  
APPENDICES  
 
Appendix A     Knowledge questionnaire in English                                                        
Appendix B     Knowledge questionnaire in Bahasa Malayu 
Appendix C     Data collection form for hospital  
Appendix D     Request letter for permission to carry out research in GH Penang     
Appendix E     Approval from clinical research committee, Ministry of Health                
                        Malaysia, General Hospital Penang 
Appendix F     Letter of appointment as a supervisor 
Appendix G    Abstract for conference 
Appendix H    Certificate of acknowledgement 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv  
PENILAIAN PENGETAHUAN TENTANG DEMAM DENGGI DALAM KALANGAN 
ORANG RAMAI SERTA PREVALENSNYA, CIRI –CIRI KLINIKAL DI HOSPITAL 
BESAR PULAU PINANG 
 
 
ABSTRAK  
 
Denggi merupakan salah satu daripada masalah kesihatan awam global yang amat penting, terutamanya 
di negara-negara Asia Tenggara. Walaupun penyakit ini telah wujud di Pulau Pinang sejak 1902, 
namun tiada bukti yang memperincikan tentang pengetahuan denggi dalam kalangan orang ramai. 
Kemunculan semula penyakit ini memerlukan suatu penilaian tentang pengetahuan yang ada pada 
orang ramai, prevalensnya, ciri-ciri klinikal dan pengurusan denggi di Pulau Pinang. Dalam kajian 
rentas-silang data dikumpul daripada orang ramai untuk menilai pengetahuan mereka tentang denggi. 
Seramai 862 responden terlibat dalam kajian ini, yang  majoritinya  (97.2%) mengetahui tentang 
denggi. Dapatan menunjukkan bahawa pengetahuan responden tentang denggi dan nyamuk aedes 
adalah mencukupi. Dari segi bangsa, didapati bahawa pengetahuan tentang denggi secara signifikannya 
adalah tinggi dalam kalangan responden berbangsa Melayu, dibandingkan dengan bangsa lain.  
Pengetahuan dalam aspek pencegahan dan gejala denggi didapati tinggi dengan perkaitan yang 
signifikan P=0.030 dan P=0.031 masing-masing,  dengan peningkatan kumpulan umur.  Suatu 
perkaitan yang positif ditemui di antara pengetahuan dan pendidikan.  Dari segi gender, responden 
wanita menunjukkan pengetahuan yang lebih baik berbanding dengan responden lelaki. Dalam kajian 
ini, ditemui bahawa responden lelaki sama ada yang bekerja, tidak bekerja, mahupun remaja secara 
signifikannya  tidak mempunyai pengetahuan yang mencukupi tentang denggi. Mereka ini perlu diberi 
perhatian khusus serta galakan untuk ikut serta dalam program pendidikan kesihatan terutamanya 
tentang denggi, yang akan diadakan pada masa depan.  Suatu kajian retrospektif dijalankan, yang 
melibatkan sejumlah 756 pesakit denggi yang dimasukkan ke wad perubatan di Hospital Besar dalam 
tempoh Januari 2007 hingga Disember 2007.  Dalam pemerhatian ini, denggi didapati dalam kalangan 
kanak-kanak dan orang dewasa. Ciri klinikal demam, ruam petekia (petechial rashes), ujian Hess 
positif, kesakitan di bahagian epigastrik, peningkatan sel darah putih, hemoglobin, hematokrit dan 
trombositopenia ditemui secara signifikan  (P<0.001) berkaitan dengan denggi. Semua pesakit sembuh 
kecuali seorang meninggal kerana sindrom kejutan denggi. Demam denggi, demam denggi berdarah 
dan sindrom kejutan denggi sepatutnya dianggap sebagai diagnosis yang berbeza. Bagi mengelakkan 
komplikasi, pengurusan bendalir secara intravena adalah mandatori, yang perlu diberi  dengan teknik 
khusus untuk mengelak daripada berlakunya lebihan cecair pada pesakit kanak-kanak dan juga pesakit 
dewasa. 
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  EVALUATION OF DENGUE FEVER KNOWLEDGE AMONG THE GENERAL 
POPULATION AND ITS PREVALENCE, CLINICAL FEATURES IN PENANG 
GENERAL HOSPITAL 
 
ABSTRACT 
 
 
Dengue is one of the most important global public health problem, particularly in South East 
Asian countries. Despite the presence of the disease in Penang since 1902, no documented 
evidence existed on the knowledge of dengue among the general population. The current 
resurgence of the disease necessitates an evaluation of public knowledge, prevalence, clinical 
features and fluid management of dengue in Penang. In cross-sectional study data were 
collected from the general population to asses the knowledge. A total of 862 respondents of 
the population were participated in the study.Majority (97.2%) of the population were familiar 
with the disease dengue. Over all knowledge about dengue and aedes mosquito was found 
adequate. In terms of races knowledge on dengue was found significantly higher in Malays 
than the other races. Knowledge on isolated aspects like preventive measures and symptoms 
of dengue was found to be high with significant association (P=0.030 and P=0.031) 
respectively, with increasing age groups. A positive association was found between 
knowledge and education. On gender base female shown good knowledge compared to male. 
In this study the teenagers, private, unemployed people and in terms of gender male had 
significantly insufficient knowledge and need a special attention and to encourage these 
groups for meaningful participation in future health education programes regarding dengue. In 
retrospective study a total of 756 in patients of dengue were observed admitted to the medical 
ward in General Hospital during the period January 2007 to December 2007 and found that 
the children and adults both were affected of dengue. The clinical features fever, petechial 
rashes, positive Hess test, epigastric pain the rise of white blood cells (WBC), haemoglobin, 
haematocrit and thrombocytopenia found a significant (P<0.001) association with dengue. All 
patients were survived except one who was found to be died of dengue shock syndrome and 
circulatory failure. Dengue fever, dengue haemorrhagic fever and dengue shock syndrome 
should be considered in a differential diagnosis of febrile illness in patients. To avoid 
complications, management of intravenous fluids is mandatory to administer with special 
technique to avoid over load of fluids both in children as well as in adults. 
1  
CHAPTER ONE 
INTRODUCTION 
 
1.0 Introduction and literature review 
 
1.1 Background 
Dengue is defined as “an acute illness caused by a virus belonging to the family 
flaviviridae, under the genus flavivirus”. Today dengue is a fast growing health 
problem in tropical and sub tropical countries and is the most common disease among 
all arthro-borne viral infection in the world today. Yearly, more than 100 million 
cases of dengue infection worldwide are anticipated to occur and become not only an 
enormous health problem but also a serious economical burden to those countries 
where dengue is endemic (World Health Organization, 1997).   
 
There are four famous serotypes of dengue virus namely as Den-1, Den-2, Den-3, 
Den-4, which  are  known  to  cause  a  wide  spectrum of nonspecific  viral  set of 
symptoms,  ranging  from  fever  and  headache  to  severe  and  fatal hemorrhagic 
disease, known as dengue hemorrhagic  fever and dengue shock syndrome. Dengue  
hemorrhagic  fever  is  a  severe  febrile  disease  that  is  characterized  by 
abnormalities of homeostasis and increased membrane permeability, also 
characteristic of dengue shock syndrome (Halstead, 1980). Infection with one 
serotype develops long life immunity against re-infection by that same serotype, but 
not against the other serotype. 
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1.2 Epidemiology and prevalence of dengue fever 
Geographically the spread, incidence and severity of dengue fever (DF) and dengue 
hemorrhagic fever (DHF) had been increased in the Americas, South-East Asia, the 
Eastern Mediterranean and the Western Pacific. It was reported that 2,500 million to 
3,000 million people live in the areas where dengue viruses can be transmitted. It was 
estimated that each year 50 million infections occurred, with 500,000 cases of DHF 
and at least 12,000 deaths (WHO, 2002). 
 
An epidemiological study was conducted on dengue epidemics in 1998 Nicaragua, 
Central America. The dengue disease is classified on the basis of disease severity. A 
total of 1,027 patients were enrolled, in which 614 (60%) of the patients were found 
confirmed a positive cases of dengue. Out of 614, 268 (44%) were classified as 
dengue fever (DF), 267 (43%) defined as DF with hemorrhagic manifestations (DF 
hem), 40 (7%) as dengue hemorrhagic fever (DHF), 20 (3%) classified as dengue 
shock syndrome and 17 (3%) as dengue with signs associated (DSAS). No secondary 
correlation was found with DHF and DSS. In this study dengue type 3 was found to 
be responsible for causing dengue. It was concluded that the epidemiology can be 
dependent on the geographical region and viral serotype (Harris et al., 2000). 
 
A retrospective study was carried out in a hospital during the outbreak of dengue in 
1996 Delhi, India. Children were studied from September to November 1996 in the 
hospital. There were a total of 134 cases of dengue, in which 80 (60%) were males 
and 54 (40%) female. All these patients were diagnosed and managed according to 
standard protocol, 92 (67%) were detected as dengue hemorrhagic fever (DHF) and 
42 (33%) as dengue shock syndrome (DSS). The symptoms observed were fever 
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(93%), abdominal pain (49%) and vomiting (68%). Haemorrhagic features observed 
were hematemsis (39%), epistaxis (36%) and skin bleed (33%). Hepatomegally was 
present in 97 (72%) patients and spleenomegally 25 (19%). Haematocrit (>40%) was 
found only in 25 (18%). So in this study it was observed that the children <6 years 
were more affected and was suggested that this may be due to increase in endemicity 
and further suggested that the DHF and DSS cases in which fluid therapy is not 
required isolated management protocol should be formulated (Aggarwal et al., 1998). 
 
In a study carried out by Gubler, (1997) observed that the characteristic of DF in the 
America during the first 70 years of 20th century was the classical DF disease and 
that the outbreaks were caused by a single virus serotype. Dengue and dengue 
hemorrhagic fever geographically expanding because both the viruses and the 
mosquito vectors had increased the outbreaks. Gubler suggested that there is a need of 
community participation in dengue’s programme.  It was also suggested that there is a 
need for research and improvement of public health infrastructure. Further it was 
emphasized on the research needed to develop more effective preventive strategies, 
including new mosquito control technology and dengue vaccines, an improved public 
health infrastructure. These strategies will help the community-based prevention 
programmes to reduce the inclination of growing epidemic dengue fever (DF) and 
dengue hemorrhagic fever (DHF). 
 
It was reported in a study  that in 1993 in the Central America (Costa Rica and 
Panama), native dengue transmission was occurred and finally in 1994 dengue virus 
serotype 3 reappeared in Nicaragua and Panama after 17 years reported by morbidity 
and mortality weekly report (MMWR, 1995). In this report clinical profile were 
observed for 40 cases out of 46 laboratory-confirmed cases. The most commonly 
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reported symptoms were presented with classic dengue fever (92%), myalgia (48%), 
rash (48%) and headache (42%). They suggested for the health care providers to 
consider dengue in a differential diagnosis for all patients. They further suggested that 
when dengue is suspected, patients should be monitored for evidence of hypotension, 
hemoconcentration and thrombocytopenia. Because of the anticoagulant properties of 
acetylsalicylic acid (i.e., aspirin), only acetaminophen products are recommended for 
management of fever. 
 
In a study conducted in Brazil, the first detected cases of dengue hemorrhagic fever 
was explored in Rio de Janeiro followed the isolation of DEN-2 in 1990.  Upto 1991, 
over 50.0% (462) of all dengue hemorrhagic fever cases were diagnosed in that area. 
In next few years the numbers of cases of dengue were noted more and observed 112 
cases per year excessive in Fortaleza, Ceara State, in Northeast Brazil. From 1995 up 
to 2000 Brazil had recorded few cases of dengue hemorrhagic fever and noted 
thousands of reported cases of classical dengue fever (DF). Majority of the people 
were over 15 years old that highly affected by dengue fever. They concluded that as 
long as a vaccine is not available, further dengue control depends on potential results 
from basic research and intervention evaluation studies, integrating environmental 
changes, community participation and education, epidemiological and virological 
surveillance, and strategic technological innovations aimed to stop transmission 
(Teixeira et al., 2002). 
 
In another study 63% of the patients had dengue shock syndrome with 
haemoconcentration, thrombocytopenia and shock. There was a high percentage 
(80%) had gastrointestinal and in 9 (30%) had complications severe enough to cause 
shock and death. So in these nine cases, the gastrointestinal hemorrhage and 
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haematemesis began before the onset of shock and there was no evidence 
haemoconcentration or pleural effusion any time during hospitalization.  In 
conclusion it was proposed that the disease should be more practically classified as 
dengue fever with or without hemorrhage and dengue shock syndrome (Suharyono et 
al., 1979). 
 
Kouri and his colleagues in their study reported that dengue hemorrhagic fever (DHF) 
and dengue shock syndrome (DSS) cases, first were reported in Cuba in 1981.  They 
reported a total of 344,203 of dengue and 10,312 out of that were of DHF and DSS 
cases and 158 cases were found critical, three main dengue outbreaks were reported 
in Cuba, one in 1977, produced by DEN-1 and characterized as classical dengue fever 
and two DHF epidemics, one in 1981 and the other in 1997, caused by DEN-2. In 
January 1997, a DEN-2 outbreak was evaluated in Santiago de Cuba municipality (in 
an eastern Cuban province). The results among adults showed that dengue 
hemorrhagic fever (DHF) and dengue shock syndrome (DSS) was characterized by 
fever (100%), gastrointestinal symptoms (90%), purpura (66%) and upper 
gastrointestinal bleeding (40%). Hepatomegaly (35%), abdominal pain (58%) and 
haematemesis (35%) were frequently recorded in fatal cases; these can be considered 
to be signs of a poor clinical prognosis. Thrombocytopenia (71%) and 
haemoconcentration (92%) were frequently observed in many cases. In children 
thrombocytopenia and haemoconcentration were observed in 78% and 97%, 
respectively. It was concluded that it should be in the notice of  international 
community that dengue can be controlled when the principles established by (PAHO) 
and (WHO) to follow strictly as this done by Cuba twice (Kouri et al., 1989). 
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In 2001, a record 69 countries from the Word Health Organization (WHO) regions of 
South East Asia, Western pacific, and the Americas reported about the existence of 
dengue. In 2002, the World Health Organization (WHO) region of the Americas were 
reported more than 1 million cases for the first time. 
 
It was reported by Scientific Working Group (SWG), research and training in tropical 
diseases (TDR) that dengue is an endemic in all of the World Health Organization 
Regions except the World Health Organization European Region (WHO, TDR, 
2002). 
 
In another study explored by Scientific Working Group (SWG) and (TDR) to the 
world health organization (WHO, 2006) that the average number of dengue cases 
occurred in specific time (yearly) in different countries of the world, from  1955 to 
1959, 908 cases were reported, in between 1960 to 1969, 15,497 cases of, 1970 to 
1979, 122,174 cases, 1980 to 1989, 295,554, cases, 1990 to 1999, 479,848 cases and   
from 2000 to 2005 925,896 cases of dengue were reported to the World Health 
Organization (WHO).   
 
A study performed in Nakhon Pathom, Thailand on the outbreak of dengue fever 
(DF) and dengue hemorrhagic fever (DHF) in the year 2001 (Thaval et al., 2006). 
The total cases of dengue hemorrhagic fevers (DHF) were reported 3112 and 393 
per/100,000 populations. Out of these volunteers 8.8 percent had a serum sample 
positive for DF and DHF virus IgM antibody. The highest prevalence was found in 15 
to 40 years of age group. As a result it was found that the high prevalence of dengue 
virus mixed with big population, urbanization and increasing the breeding chances of 
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mosquitoes. It was suggested to observe the evaluation of viral transmission at the 
time of outbreak and later. This shows the importance to inform people and control 
the virus transmission and is necessary for personal protection. 
 
In endemic Asian countries where there was a simultaneous transmission of multiple 
serotypes and cyclical epidemics, primary dengue infection usually occurred in young 
children and created few symptoms.  Ocassionaly; severe dengue was noted in infants 
less than one year of age and was credited to the presence of maternal antibody (Kliks 
et al., 1988).  In general, symptomatic dengue and severe disease, mostly associated 
with secondary or repeat infections, occur in older children (Burkie et al., 1988; 
Thein et al., 1997). As shown in the table below, 25% to 37% of symptomatic dengue 
requiring hospitalization was reported in children in 5 to 9 years of age.  
 
  Table 1.1  Age distribution of dengue cases from hospital based studies in hyper 
endemic Asian countries. 
 
 
 
 
 
 
 
 
Percentage of cases by age group 
Hospital and year Diagnosis and       number (n) < 5 
years 
5- 9 
years 
10 to 14 
years 
> 15 
years 
S. L. Hospital, Manilla, 
Philipines ,1983 -1984 
(Hayes et al., 1998) 
Laboratory-
confirmed dengue 
cases, n = 517 
15% 36% 26% 23% 
Children’s Hospital No1,    
H. C. M. City, Vietnam 
1996 (Lan   et al., 1998) 
Clinically suspected 
Cases, n = 4,011  34% 37% 29% NA 
M .H. Hospital and C. 
Hospital ,  Palembang, 
South Sumatra, 
Indonesia,1998 
(Crown et al., 2001) 
Clinically suspected 
dengue cases,              
n = 1,772 
16% 25% 59% NA 
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 Table 1.2 Incidence of laboratory-confirmed symptomatic dengue from 
population based prospective studies in hyper endemic Asian countries 
 
 
In one of the study performed on the epidemiology of dengue reported that in some of 
the countries gradually the older age groups became a victim of dengue attack (Guha-
Sapir., 2005), this was dramatically seen in Singapore where they had successfully 
controlled the mosquito. Recently it was reported, that  less than 1% of children 10 
months to 5 years old and only 7% of those 6 to 10 years of age were found to have 
dengue antibodies (Ooi et al., 2001 ) and high dengue mortality was moved from 
children to adults (Goh,1997 ). 
 
The dengue fever that was observed in children, in Latin American and Carribean 
countries was found to be more severe than the hyper endemic Asian countries. In 
these countries both adults and children were affected by dengue and in some 
epidemic areas only adults were affected (Guzman and Kouri, 2003). 
Study site PopulationSize 
Age 
range 
Study 
period Incidence 
Yan ,Myanmar 
(Thein et al.,1997)      12489 
 
1 to 9 
years 
1984 to1988
 
0.3%  (hospitalized 
dengue cases/year) 
Bangkok, Thailand 
(Burke et al.,1988) 1757 4 to 16 yrs
Jun 1980 to  
Jan 1981 
0.7%  (symptomatic 
dengue cases over 
one season) 
Yogyakarta, 
Indonesia (Graham 
et al.,1999) 
1837 4 to 9 years 1995 to1996
3.6%  (symptomatic 
dengue cases over 
one season) 
      2119 Jun 1998 to Nov 1998 
3.3%  (symptomatic 
dengue cases over 
one  season) 
1928 Jun 1999 to Nov 1999 
0.8%  (symptomatic 
dengue cases over 
one  season) 
Kamphaeng phet,    
Thailand  (Endy et 
al., 2002) 
1713 
 
7 to  
11years 
Jun 2000 to 
Nov 2000  
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1.3 Prevalence in Malaysia   
Malaysia is located in the tropics, dengue is a major problem for its people.  Dengue 
fever was first reported in 1902 in Penang (Skae, 1902) and had become a major 
public health problem in Malaysia. As DHF outbreak was first appeared in Penang in 
1962 (Rudnick, et al., 1965). Notification of DF and DHF in Malaysia was reported 
in 1971. It has reported that the incidence rate of clinically diagnosed DF and DHF 
increased from 8.5 cases/100,000 population in 1998 to 123.4 cases/100,000 
population in 1998. In the year 2001, out of 16,368, 22% cases were reported among 
children 14 years and below. In the year 2001, the DH: DHF ratio in children to 
adults was found to be 6.7:1 (Ministry of Health, Malaysia, 1988-2001). 
 
The incidence of both dengue fever (DF) and dengue hemorrhagic fever (DHF) in 
Malaysia has increased. The case fatality rates (CFR) however, seem to be stable. 
Many reported cases cannot be confirmed due to the lack of a second blood specimen. 
Of the confirmed cases, about 5 % were DHF as seen in Table 1.4.  
 
                               Table 1.3 Dengue fever in Malaysia 1999-2003 
 
Confirmed 
cases 
Year 
 
Population 
CFR 
 
 
Reported 
cases 
 DF DHF 
Incidence 
/100,000 Deaths 
1999 22,711,900 10,146.78 4,718 - 20.77 37 
2000 23,226,700 71,181.21 3,312 411 16.03 45 
2001 23,795,300 16,368.58 8,277 392 36.43 50 
2002 24,374,300 32,767.64 14,694 799 63.56 99 
2003 25,048,300 31,545.47 14,761 681 61.65 72 
DF = Dengue fever, DHF = Dengue-hemorrhagic-fever, CFR = Case-fatality-rate                     
       Adaptation, vector borne disease section, Ministry of Health, Malaysia 
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Table 1.4 Dengue deaths and case fatality rates by age in Malaysia (1999-2003)  
Year         Age <5 years Age 0-14 years  Age> 15 years 
 Total 
Cases 
Total 
deaths CFR 
Total 
cases 
Total 
deaths 
CFR 
 
Total 
cases 
Total 
deaths CFR 
1999 457 3 0.66 2,045 19 0.09 8,101 18 0.22 
2000 373 12 3.22 1,432 19 1.33 2,291 26 1.3 
2001 863 7 0.81 3,605 23 .64 5,064 27 0.53 
2002 130 17 13.08 2,284 47 2.07 13,209 52 0.39 
2003 469 11 2.35 3,096 29 0.94 12,346 43 0.35 
 (Adaptation: Ministry of Health Malaysia, Vector-Borne Diseases Section, Annual 
Report) 
 
According to the Ministry of Health, Malysia, 2007,  in the below figure the number 
of reported dengue fever (DF) and dengue hemorrhagic fever (DHF) cases in 
Malaysia had increased as displayed in the  figure 1. 
 
The incidence rate also has increased from 44.3 cases/100,000 population in 1999 to 
181 cases/100,000 population in 2007, Figure 2. This exceeded the national target for 
the incidence rate of DF and DHF which was kept less than 50 cases/100,000 
population.  
The incidence rate was found higher in the age group of 15 years and above (Figure 
2). The highest incidence rate found among the working and school-going age groups. 
An increase of dengue deaths in the adult population had been observed since 2002, 
Figure 3.  
The case fatality rates for both DF and DHF have remained below 0.3% since 2002 in 
Figure 4.  
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                 Figure 1.1 Number of dengue cases, Malaysia 1995-2007 
 
   Adapted from annual report vector borne disease section (Ministry of Health,        
   Malaysia; 2007) 
 
 
 
 
      Figure 1.2 Dengue incidence rate by age group in Malaysia, 2003, 2007 
    Adapted from annual report vector borne disease section (Ministry of Health,     
     Malaysia; 2007). 
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     Figure 1.3 Dengue deaths by age group, Malaysia 
       Adapted from annual report vector borne disease section (Ministry   
                      of Health, Malaysia; 2007). 
 
 
 
       Figure 1.4 Dengue case fatality rate (CFR) by age group, Malaysia   
   
      Adapted from annual report vector borne disease section (Ministry   
             of Health, Malaysia; 2007). 
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1.4 Disease Transmission   
The bite of an infectious female mosquito transmits dengue to humans. The Aedes 
aegypti mosquito usually rests in dark, indoor sites such as closets and under beds and 
is primarily a day time feeder, biting mainly in the morning or late afternoon. The 
female mosquito lays its eggs often in the artificial containers. Larvae are often found 
in the containers with relatively clean water, such as discarded tires, buckets, 
flowerpots and flower vase, drums, blocked rain gutters. Larvae can also found in 
natural sites such as bromeliads (types of plants) and tree holes. 
 
The transmission cycle of dengue virus begins when the female mosquito bites a 
viremic person. Eight to twelve days that is extrinsic incubation period to pass before 
the mosquito becomes infective.  It can then transmit the virus throughout its lifetime 
whenever it bites or even search the skin of another person. Once the virus is 
inoculated into the susceptible human, it replicates in the local lymph nodes and the 
liver (Gubler et al., 1979). The virus is then released from these tissues and infects 
white blood cells (WBCs) and distant lymphatic tissues, circulates in the blood and is 
eventually cleared by the host immune response.  The incubation period for disease in 
humans (intrinsic incubation period) may range from 3 to 14 days and most often 
lasts between 4 and 7 days. 
 
The virus is transmitted by the Aedes mosquito, of which the Aedes aegypti is the 
principal vector (Pang, 1983). Aedes aegypti is mostly domesticated mean found in 
urban areas. While another vector Aedes albopictus mostly survive in the rural setting 
(Lam, 1993). Dengue viruses are transmitted to humans by the bite of infective 
female mosquitoes of the genus Aedes, although Aedes albopictus and Aedes 
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polynesienses are both also involved in dengue outbreaks. It has been estimated that 
50 to 100 million cases of dengue fever and 500,000 cases of dengue hemorrhagic 
fever (DHF) and as a result approximately 24,000 deaths take place, are reported 
annually  (Porter et al., 2005; WHO,1997). 
 
1.5 Virology 
                                        
Dengue infection is caused by dengue virus which is a mosquito-borne flavivirus. 
Dengue transmitted by Aedes aegypti and Aedes albopictus. Growth of the 
population, rural–urban migration, no proper urban infrastructure and growth of 
consumerism are responsible for favorable conditions, causing viral transmission by 
the mosquito vector, Aedes aegypti (WHO, 1997). There are four distinct serotypes, 
DEN-1, 2, 3 and 4. Each infection induces a life-long protective immunity to the 
homologous serotype but gives a partial and brief protection against succeeding 
infection by the other three serotypes. Secondary infection is a major risk factor for 
DHF due to antibody-dependent enhancement. Other important contributing factors 
for DHF are involved viral virulence, host genetic background, T-cell activation, viral 
load and auto-antibodies. 
 
According to MOH annual report, 2007 in the analysis of dengue serotypes from 
1991 – 2007 all four serotypes are found in Malaysia. But DEN-3 was the 
predominant serotype in 1993 and then declined.  It was then reproduced, reaching 
the peak in 2001. Other serotypes were also observed co-circulating at the same time 
(Annual report 2007; Ministry of Health, Malaysia). 
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1.6 Clinical features (manifestations) and pathophysiology 
1.6.1 Spectrum of dengue infection 
The incubation period for dengue infection is 4-7 days (ranging 3-14) reported by 2nd 
edition, WHO, 1997. This disease can be asymptomatic or may result in a spectrum 
of illness starting from undifferentiated mild febrile illness towards severe disease, 
with or without plasma leakage and different organ impairment. Symptomatic dengue 
infection is a systemic and active disease with clinical, hematological and serological 
profiles changing from day to day. These changes speed up by the hour or even 
minutes during the critical phase, particularly in those with plasma leakage. 
 
 
1.6.2 Clinical course of dengue infection 
 
Dengue infection is an active disease.  Its clinical route changes as the disease grows. 
After the incubation period, the illness begins rapidly and will be followed by 3 
phases, febrile, critical and recovery phase (Nimmannitya, 1987; Gubler, 1998).  
1.6.2.1 Febrile phase  
 
 Normally patients develop high grade fever suddenly. In this acute febrile phase the 
fever usually lasts 2-7 days and the face becomes flush, other characteristics skin 
erythema, generalized body ache, myalgia, arthralgia and headache (Nimmannitya, 
1987; Gubler, 1998).  Some patients may suffer of sore throat, injected pharynx and 
conjunctival injection. Anorexia, nausea and vomiting are common features. These 
clinical features were indistinguishable between DF and DHF (Kalayanarooj et al., 
1997). Mild hemorrhagic manifestations like positive tourniquet test or petechia and 
mucosal membrane bleeding can be seen in DF and DHF (Kalayanarooj et al., 1997; 
Balmaseda et al., 2005). Per vaginal bleeding is common among young female adults. 
Vast vaginal bleeding and gastrointestinal bleeding may occur during this phase but 
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are not common (Hammond et al., 2005; Balmaseda et al., 2005). The liver is often 
enlarged and tender after a few days of fever in DHF (Kalayanarooj et al., 1997). 
 
 
1.6.2.2 Critical Phase 
 
This critical phase occurs at the time of late febrile phase (often after 3rd day of 
fever) or around defervescence (usually between 3rd day to 5th day of illness but may 
go up to 7th day) when a rapid drop in temperature may match with an increase in 
capillary permeability in some patients. In other viral infections, the patient’s 
condition improves as the temperature falls down but different in DHF. At this point 
the patient will either become better or least plasma leak occurs or worse if critical 
volume of plasma is lost (Nimmannitya, 1987; Gubler, 1998; Guzman et al., 1997; 
Rigau, 2006). 
 
The critical phase remains for about 24 to 48 hours.  In less severe cases, these 
changes are least and for short time. Many of these patients recover spontaneously, or 
after a short period of fluid or electrolyte therapy.  In more severe form of plasma 
leakage, the patients could sweat, become restless, have cool extremities and 
prolonged capillary fill up time. The pulse rate increases, diastolic blood pressure 
increases and the pulse pressure narrows. Abdominal pain and vomiting, restlessness, 
altered conscious level and a sudden change from fever to subnormal temperature 
were stated as the clinical alarm signals of shock ( Rigau and Laufer ,2006; Ong et 
al., 2007; Wichmann et al., 2004). The patient can progress rapidly to deep shock and 
death if on time fluid resuscitation is not administered. 
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Leucopenia with relative lymphocytosis, clotting abnormalities, elevation of 
transminases (typically the level of aspartate aminotransaminase (AST) is about 2-3 
times the level of alanine aminotransaminase (ALT), hypoproteinaemia and 
hypoalbuminaemia are usually observed stated by (Nimmannitya, 1987; Gubler, 
1998; Kalayana-rooj et al., 1997). 
 
 
1.6.2.3 Recovery phase 
 
 After 24 to 48 hours of defervescence, plasma leakage stops and is followed by 
reabsorption of extravascular fluid. Patients’ generally improves, appetite returns, 
gastrointestinal symptoms decrease, hemodynamic status stabilizes and diuresis 
develops. Some patients may have a classical rash of “island of white in the sea of 
red” ( Nimmannitya, 1987). 
Some may have generalized pruritus. Bradycardia and electrocardiographic changes 
may occur during this stage. It is important to note that during this phase, haematocrit 
(Hct) level stabilizes or drops further due to haemodilution following reabsorption of 
extravascular fluid. The recovery of platelet count is typically preceded by recovery 
of WBC count.   
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Fig 1.5 Clinical course of dengue of DHF (Nimmannitya, 1987; Gubler. 1998) 
 
Clinical worsening mostly happens at the time of the critical phase (plasma leakage) 
therefore, it is significant to identify the onset of this phase. The onset of critical 
phase is manifest by plasma leakage and usually occurs around the beginning of 
defervescence. Indication of plasma leakage includes raised Hct (early marker), 
hemodynamic instability, fluid accumulation in extra vascular space (rather late 
marker) or hypoproteinemia. Abdominal pain and vomiting, restlessness, altered 
conscious level and a sudden change from fever to subnormal temperature are the 
clinical alarm signals of shock. 
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1.7 Pathophysiology of plasma leakage in dengue hemorrhagic fever (DHF) and 
dengue shock syndrome (DSS). 
 
The primary pathophysiological abnormality seen in DHF and DSS is a quick 
increase in vascular permeability that leads to leakage of plasma into the extra 
vascular compartment, resulting as a haemoconcentration and hypovolaemia or shock 
(Cohen et al., 1987; Gubler, 1998). Hypovolaemia leads to reflex tachycardia and 
generalized vasoconstriction due to increased sympathetic output; (Pongpanich, 1973; 
Ganong, 2005). Clinical manifestations of vasoconstriction in various systems are as 
follows: 
a. Skin - coolness, pallor and delayed capillary refill time. 
b. Cardiovascular system - raised diastolic blood pressure and a narrowing pulse 
pressure. 
c. Renal system - reducing urine output 
d. Gastrointestinal system - vomiting and abdominal pain 
e. Central nervous system – lethargy, restlessness, apprehension, reduced level of 
    consciousness. 
f. Respiratory system – tachypnoea (respiratory rate > 20/min) 
 
In those patients whose consciousness is not mentally dulled, powerful thirst is 
another important symptom. At the same time, the inadequate perfusion of the tissue 
leads to increased anaerobic glycolysis and resultant lactic acidosis. If the 
hypovolaemia is not corrected quickly, the patient will progress to refractory shock 
state. The tissue perfusion would not respond to vasopressor drugs, even if the blood 
pressure and intravascular volume were to be restored and cardiac output would 
remain depressed. 
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The resultant lactic acidosis further depresses the myocardium and worsens the 
hypotension (Ganong, 2005). The common late complications of prolonged shock are 
huge, bleeding, disseminated intravascular coagulopathy (DIC) and multi organ 
failure which are mostly lethal. 
 
 
Table 1.5 A ranges of pathophysiological changes from normal circulation to 
compensated and decompensated hypotensive shock by Ganong WF, 2005 
 
 
 
The pathogenetic mechanism which is responsible for the increased vascular 
permeability in DHF/DSS is not yet known. There are no clear destructive vascular 
lesions to describe for this increased vascular permeability but on post-mortem 
(microscopically), perivascular oedema and loss of integrity of endothelial junctions 
with endothelial dysfunction are found (Bhamarapravati, 1967; Sahaphong et al., 
1980). Abnormal immune response involving the production of cytokines or 
Normal circulation Compensated shock Decompensated hypotensive shock 
Clear consciousness 
 
Clear consciousness –shock 
can be missed if you do not 
touch the patient 
Change of mental state –
restless, aggressive or lethargy
Fast capillary refill time 
<2 sec 
Prolonged capillary refill time 
>2 sec 
Mottled skin, very prolonged 
capillary refill time 
Warm and pink 
extremities Cool extremities Cold, clammy extremities 
Good volume peripheral 
pulses 
Weak & thready 
peripheral pulses 
Feeble or absent peripheral 
Pulses 
Normal heart rate for age Tachycardia Severe tachycardia with bradycardia in late shock 
Normal blood pressure 
for age 
Normal systolic pressure with 
raised diastolic pressure 
postural hypotension 
Hypotension/ unrecordable 
BP 
Normal pulse pressure for 
age Narrowing pulse pressure 
Narrowed pulse pressure (<20 
mmHg) 
Normal respiratory rate  
for age Tachypnoea 
Metabolic acidosis/ 
hyperpnoea/ Kussmaul’s  
breathing 
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chemokines, activation of T-lymphocytes and disturbances of haemostatic system are 
the major changes seen in DHF. Mediators including C3a, C5a, tumor necrosis factor-
α, interleukin 2, 6 and 10, interferon-α and histamine are elevated (Gubler, 1998; 
Chuansumrit and Tangnararatchakit, 2006). 
 
Secondary infection with a heterotypic dengue virus is associated with increased risk 
of developing dengue hemorrhagic fever (DHF).  It is believed that DHF is occured 
due to antibody-dependent enhancement phenomenon (Halstead, 1970; Sangkawibha 
et al., 1984; Guzman et al., 2002).  The sub-neutralizing concentration of the cross-
reacting antibody from the previous infection may opsonise (making the virus 
susceptible) and enhances the virus uptake and replication in the macrophage or 
mononuclear cells. The level of T-cell activation is also enhanced. Profound T-cell 
activation with cell death during acute dengue infection may suppress or delay viral 
elimination, leading to the higher viral loads and increased immunopathology found 
in patients with DHF (Gubler, 1998, Chuansumrit et al., 2006). 
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1.8 Assessment of the WHO classification and case definitions 
 
 
 
 
 
 
 
Figure 1.6 World health organizations (WHO) Dengue classification 
 
The WHO case definitions of dengue fever (DF), dengue hemorrhagic fever (DHF), 
and dengue shock syndrome (DSS) are described below. Due to the unpredictability 
in the clinical illness associated with dengue infection, the WHO guidelines stress the 
need for laboratory confirmation (WHO, 1997). 
Probable dengue fever (DF) is an acute febrile illness with two or more of the 
following manifestations. 
Headache, retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestations, 
leucopenia and supportive serology or occurrence at the same location and time as 
other confirmed cases of dengue. 
Confirmed DF is characterized by laboratory criteria (isolation of dengue virus, four 
fold or greater change in antibody titres, demonstration of the dengue virus antigen or 
genomic sequence.) 
To fulfill the WHO case definition for DHF, the following must all be present. 
i)  History of acute fever, lasting 2-7 days, occasionally biphasic. 
ii) Bleeding (hemorrhagic tendencies), evidenced by at least one of the following 
Symptomatic dengue 
infection 
No shock 
Dengue fever Dengue haemorr-    
      agic fever 
Undifferentiated 
fever 
With unusual
haemorrhagic 
Without 
haemorrhagic 
Dengue shock 
syndrome 
23  
A positive tourniquet test (TT), petechiae, ecchymosis, or purpura, bleeding, bleeding 
from the mucosa, gastrointestinal tract, injection sites or other locations, 
haematemesis or melena, thrombocytopenia (100,000 cells per mm3 or less).  
iii) Evidence of plasma leakage due to increased vascular permeability, manifested by 
at   least one of the following. 
A rise in the haematocrit equal or greater than 20% above average for age, sex and 
population. A drop in the haematocrit following volume replacement treatment equal 
to or greater than 20% of baseline. Signs of plasma leakage such as pleural effusion, 
ascites and hypoproteinemia.  
iv) To fulfill the case definitions for DSS, the four criteria above for DHF (fever, 
hemorrhaged tendencies, thrombocytopenia and plasma leakage) must all be present 
plus evidence of circulatory failure manifested as: rapid and weak pulse, narrow pulse 
pressure (<20mmHg) or hypotension for age (this is defined as systolic pressure 
<80mmHg for those less than five years of age, or <90mmHg for those of five years 
of age or older. 
v) Cold sweaty skin and restlessness. 
In the WHO guidelines, DHF is also classified on the basis of severity. Grade I is 
defined as fever and non-specific legitimate signs and symptoms; the only 
hemorrhagic manifestation is a positive tourniquet test and/or easy bruising.  
Grade II is the same as grade I but it includes spontaneous bleeding, usually in the 
form of skin or other haemorrhages. Grade III is manifested by circulatory failure, by 
a rapid, weak pulse and narrowing of the pulse pressure or hypotension, along with 
cold, clammy skin and restlessness. Grade IV is profound shock with undetectable 
blood pressure or pulse (For Grades III and IV define DSS (WHO, 1997). 
 
24  
In addition, the WHO guidelines provided a list of indicators that may be used to 
guide the diagnosis of DHF/DSS. These indicators may be helpful for clinicians to 
establish an early diagnosis, ideally before the onset of shock but are not proposed to 
be alternate for the case definitions. The listed indicators of DHF/DSS are: high fever 
of acute onset, hemorrhagic manifestations (at least a positive TT), hepatomegaly, 
shock, thrombocytopenia and haemoconcentration. The first two clinical 
observations, plus one of the laboratory findings establishes a temporary diagnosis of 
dengue hemorrhagic fever (DHF). The presence of shock in a patient with a 
provisional (interim) diagnosis of DHF supports the diagnosis of DSS (WHO, 1997). 
 
1.9 Tourniquet test (TT) 
One of the criteria for diagnosis included in the WHO case definition and in 
published protocols is the tourniquet test (TT), which is a measure of capillary 
fragility and thrombocytopaenia. The WHO guidelines specify that a blood pressure 
cuff should be inflated on the upper arm to a point midway between the systolic and 
diastolic pressures for five minutes and then the number of resulting petechiae in an 
area 6.25 cm2 (2.5×2.5 cm) should be counted. The TT is considered positive when 
20 or more petechiae are observed within the square inch (WHO, 1999; Phuong et al., 
2004). 
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1.10 Other important manifestations 
  The following manifestations are important in dengue infection but are often    
   under-recognized or misdiagnosed. 
 
 
1.10.1 Acute abdomen: 
 
Acute abdominal pain is a common symptom in dengue infection. It can be due to 
hepatitis, acalculous cholecystitis, shock and occasionally misdiagnosed as acute 
appendicitis (Khor et al., 2006; Premaratna et al., 2007). The history of onset of fever 
before that of abdominal pain and laboratory findings of leucopenia, 
thrombocytopenia or prolonged APTT with normal PT help to differentiate acute 
abdominal pain due to dengue infection from other surgical causes (Khor et al., 
2006).  Furthermore, in shock cases, the abdominal pain is relieved by the intravenous 
fluid therapy. 
 
 
1.10.2. Hepatitis and liver failure: 
 
 Hepatitis is common in patients having DF and DHF and may be mild or severe in 
spite of the degree of plasma leakage. In some cases, liver failure may occur 
(Badyopadhyay et al., 2006). The patients with liver failure have high tendency to 
bleed especially gastrointestinal bleeding (Nguyen, 1999; Wichmann, 2004). 
 
 
1.10.3. Neurological manifestation:  
 
Patients with dengue infection may have neurological manifestations (<1%) mainly 
encephalitis or encephalopathy (Solomon et al., 2000). Other unusual manifestations 
include myelitis and Guillain Barre Syndrome (Soares et al., 2006).  
 
 
 
